Clinical effectiveness of exenatide in diabetic patients waiting for bariatric surgery

What Was Tested

Researchers studied Exenatide in this clinical trial publication.

The aim of the study was to evaluate, in clinical practice, weight and metabolic effects of exenatide (after 3 and 6 months) in patients with type 2 diabetes and obesity waiting for bariatric surgery.

Why It Was Studied

Clinical experience with exenatide in obese patients with type 2 diabetes waiting for bariatric surgery has not been reported.

Who Took Part

According to the abstract, 2 patients were involved.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

A total of 100 diabetic adult subjects with a BMI ≥ 35 kg/m(2) were included.

Primary endpoints were changes in weight and HbA1c after 6 months of treatment.

How the Study Was Run

The timeline in the abstract includes 6 months.

Secondary endpoints were changes from baseline of a variety of clinical measures (triglycerides levels, blood pressure, and waist circumference).

Data were analyzed at 3 and 6 months of follow-up.

What Was Measured

PubMed files the paper under topics including Bariatric Surgery, Blood Glucose, Blood Pressure, Diabetes Mellitus, Type 2, Exenatide, Glucagon-Like Peptide 1 and Hypoglycemic Agents.

What This Means in Plain Language

This is a clinical trial of Exenatide in 2 patients over 6 months.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2015 (Obesity surgery), a journal based in United States.

More context: the Exenatide compound page, all human trials.